Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sage Therapeutics : Biogen bets on depression drug in $1.5 bln deal with Sage Therapeutics

11/27/2020 | 08:17am EST

Nov 27 (Reuters) - Biogen Inc will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders, the two companies said on Friday. The deal will give Biogen access to zuranolone, an oral therapy being developed for major depressive disorder (MDD) and postpartum depression as well as SAGE-324, which is being developed for essential tremor and other neurological disorders.

An estimated 16 million Americans experience symptoms of MDD each year, according to the U.S. Center for Disease Control and Prevention.

Analysts said the agreement will help strengthen Biogen's pipeline with two treatments that have blockbuster potential at a time when it faces uncertainty over approval of its experimental Alzheimer's drug, aducanumab.

Under the terms of the agreement, Biogen will buy about 6.2 million newly issued shares of Sage for $104.14 apiece, a 26% premium to Sage's Wednesday closing price.

Apart from the $1.525 billion in cash, Sage will also be eligible to get up to $1.6 billion in potential milestone payments.

Biogen will jointly market the drugs in the United States and get the exclusive rights to sell the drugs outside of the country, excluding rights to zuranolone in Japan, Taiwan and South Korea.

Shares of Sage, which entered the depression drugs market in 2019 with its postpartum treatment, Zulresso, fell nearly 6% in afternoon trading.

Jefferies analyst Andrew Tsai said investors might be worried about the timing of deal as Sage is likely to report data from late-stage trial of zuranolone in first half of 2021 that are largely expected to be positive.

"Investors will ask, why do the deal for less now, as opposed to waiting for positive data in 2021, which is only three to six months away," Tsai said. (Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -0.25% 269.44 Delayed Quote.10.04%
SAGE THERAPEUTICS, INC. -4.21% 88.55 Delayed Quote.2.36%
All news about SAGE THERAPEUTICS, INC.
01/22SAGE THERAPEUTICS : BMO Capital Downgrades Sage Therapeutics to Market Perform F..
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/19SAGE THERAPEUTICS : Wedbush Adjusts Price Target on Sage Therapeutics to $98 Fro..
MT
01/07SAGE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other E..
AQ
01/07SAGE THERAPEUTICS : Provides 2021 Corporate Strategy Update at J.P. Morgan Healt..
BU
01/04SAGE THERAPEUTICS : Guggenheim Upgrades Sage Therapeutics to Buy From Neutral, S..
MT
01/04SAGE THERAPEUTICS : RBC Downgrades Sage Therapeutics to Sector Perform From Outp..
MT
2020SAGE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
2020SAGE THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Confere..
BU
2020SAGE THERAPEUTICS : Names Barry Greene CEO
MT
More news
Financials (USD)
Sales 2020 7,04 M - -
Net income 2020 -473 M - -
Net cash 2020 1 245 M - -
P/E ratio 2020 -9,76x
Yield 2020 -
Capitalization 5 161 M 5 161 M -
EV / Sales 2020 556x
EV / Sales 2021 14,4x
Nbr of Employees 675
Free-Float 87,7%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | SAGE | US78667J1088 | MarketScreener
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 99,30 $
Last Close Price 88,55 $
Spread / Highest target 113%
Spread / Average Target 12,1%
Spread / Lowest Target -20,9%
EPS Revisions
Managers and Directors
NameTitle
Barry E. Greene President, Chief Executive Officer & Director
Kevin Paul Starr Chairman
Michael Cloonan Chief Operating Officer
Kimi E. Iguchi Chief Financial Officer & Treasurer
Albert J. Robichaud Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SAGE THERAPEUTICS, INC.2.36%5 161
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059